Mechanism of Action
The drug acts in the terminal portion of the distal convoluted tubules and the collecting ducts.
Its target is the epithelial sodium channel (ENaC) located on the apical membrane of principal cells. Triamterenum acts as a direct blocker: it physically obstructs the pathway for sodium ion entry through the channel.
To understand the pharmacology of this class, it is important to distinguish this mechanism from aldosterone antagonists (e.g., Spironolactonum). Antagonists work intracellularly by blocking mineralocorticoid receptors and inhibiting the synthesis of new ENaC channels, whereas triamterene directly inhibits pre-existing channels.
Pharmacological Effects
A key feature of the drug is its unique ability to enhance $Na^+$ excretion while retaining $K^+$ and $Mg^{2+}$ ions in the body.
- Potency: Its intrinsic diuretic effect is mild to moderate. It is significantly less potent than thiazide and loop diuretics. Within its narrow subclass, it is also somewhat weaker than amiloride.
- Duration: The effect lasts for 6–8 hours.
- Effect on Homeostasis: The drug does not disturb acid-base balance, and its activity is independent of luminal pH.
Indications for Use
- Correction of Electrolyte Imbalances: Potent diuretics (loop, thiazide, and thiazide-like) share a common adverse effect: they induce hypokalemia and hypomagnesemia. The rationale for prescribing triamterene is to counteract these losses. It is used strictly as part of combination therapy (a classic example is hydrochlorothiazide + triamterene).
- Liddle Syndrome: This is a rare monogenic form of hereditary hypertension. The pathogenesis involves mutations in the ENaC channels that lead to their constitutive hyperactivity. Direct epithelial sodium channel blockers are the drugs of choice for the targeted management of this condition.
Side Effects and Toxicity
Specific drug toxicity associated with triamterene stems from the fact that it is a folic acid antagonist (sharing this risk profile with the antineoplastic drug methotrexate and the antiprotozoal drug pyrimethamine).
The drug can impair folate metabolism and DNA synthesis. As a consequence, its administration may precipitate iatrogenic megaloblastic anemia (macrocytic hyperchromic anemia).
Management of Complications: If deficiency develops, folic acid is administered orally at 5 mg/day for 20–30 days. It is an essential hematology rule that if a patient concurrently has pernicious anemia, isolated administration of folic acid without vitamin B12 is strictly contraindicated, as it fails to halt neurological deterioration.
Administration and Prescription
Due to its relatively short half-life (6–8 hours), the drug is administered in multiple daily doses—ranging from 2 to 4 times a day. Administration should occur strictly in the first half of the day to avoid nocturnal diuresis that disrupts the patient's sleep.
While basic methodological guidelines suggest taking it preferably on an empty stomach, specific capsule formulations are often prescribed after meals to minimize gastrointestinal irritation.
Prescription Example:
Rp.: Caps. Triamtereni 0.05 D.t.d. N. 50 S. Take 1–2 capsules orally twice daily after meals (in the first half of the day).